Journal
CELL REPORTS
Volume 1, Issue 4, Pages 325-333Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2012.02.010
Keywords
-
Categories
Funding
- McGill Faculty of Medicine Internal Studentship
- Canadian Institutes of Health Research [MOP-106530]
- NIH [GM-073855]
- NCI program project grant [CA087497-11]
- Mouse Models of Human Cancer Consortium
Ask authors/readers for more resources
The energetically demanding process of translation is linked to multiple signaling events through mTOR-mediated regulation of eukaryotic initiation factor (eIF)4F complex assembly. Disrupting mTOR constraints on eIF4F activity can be oncogenic and alter chemotherapy response, making eIF4F an attractive antineoplastic target. Here, we combine a newly developed inducible RNAi platform and pharmacological targeting of eIF4F activity to define a critical role for endogenous eIF4F in Myc-dependent tumor initiation. We find elevated Myc levels are associated with deregulated eIF4F activity in the prelymphomatous stage of the E mu-Myc lymphoma model. Inhibition of eIF4F is synthetic lethal with elevated Myc in premalignant pre-B/B cells resulting in reduced numbers of cycling pre-B/B cells and delayed tumor onset. At the organismal level, eIF4F suppression affected a subset of normal regenerating cells, but this was well tolerated and rapidly and completely reversible. Therefore, eIF4F is a key Myc client that represents a tumor-specific vulnerability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available